ArticleFrontiers in oncology2026
Age and CIRS-G for risk stratification in elderly esophageal squamous cell carcinoma patients receiving definitive chemoradiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify prognostic factors in elderly squamous cell carcinoma (ESCC) patients receiving definitive chemoradiotherapy (dCRT) and construct a prognostic risk stratification model for identifying high-risk subgroups among elderly patients. Methods: ESCC patients aged ≥ge years receiving dCRT were enrolled. Baseline Cumulative Illness Rating Scale-Geriatrics (CIRS-G), Geriatric Nutrition Risk Index (GNRI), Systemic Immune-Inflammation Index (SII), clinical characteristics and adverse events were collected. Cox regression identified independent prognostic factors, with proportional hazards assessed by Schoenfeld residual tests and 95% confidence intervals validated by 1000 bootstrap resamples. Restricted cubic spline (RCS) curves evaluated potential cutoff values. Survival was analyzed by Kaplan-Meier method and compared by log-rank test. Results: 88 patients were enrolled. Multivariate analysis identified age (HR 1.047, 95% CI 1.000-1.095) and CIRS-G (HR 1.179, 95% CI 1.014-1.376) as independent predictors of OS, whereas GNRI (HR 0.964, 95% CI 0.932-0.995) independently predicted PFS. Schoenfeld tests confirmed proportional hazards (all P > 0.05), with bootstrap resampling supporting coefficient stability. Cutoffs were set at 75 years for age, 7 for CIRS-G, and 98 for GNRI. A prognostic score combining age and CIRS-G stratified patients into low-risk (0-1) and high-risk (2) groups, with high-risk patients showing significantly inferior OS. GNRI ≥98 correlated with prolonged PFS versus <98. The high-risk group had higher neutropenia/leukopenia (15.0% vs. 6.3%) and pneumonitis (5.0% vs. 2.1%), with exclusive thrombocytopenia/anemia (2.5% each). Conclusions: A composite risk score (age ≥75 years plus CIRS-G ≥7) identified a high-risk subgroup with poor OS. The optimal therapeutic strategy for this subgroup warrants prospective interventional trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.